Long-term rituximab safe for patients with wegener's

July 2, 2012
Long-term rituximab safe for patients with wegener's
Repeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis with polyangiitis (GPA; Wegener's), a primary systemic small vessel vasculitis, according to a study published online June 21 in Arthritis & Rheumatism.

(HealthDay) -- Repeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis with polyangiitis (GPA; Wegener's), a primary systemic small vessel vasculitis, according to a study published online June 21 in Arthritis & Rheumatism.

Rodrigo Cartin-Ceba, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues examined the efficacy and safety of B-cell depletion in 53 with refractory who had received at least two courses of rituximab for relapses or to remain in remission. All patients except one had antineutrophil cytoplasmic antibodies (ANCA) against proteinase 3 (PR3).

Patients received a median of four courses of rituximab treatment. The researchers found that B cells were depleted in all cases, returning after a median of 8.5 months. All relapses occurred after B cells were reconstituted, and all except one were accompanied or preceded by an increase in ANCA levels. There were infusion-related adverse events in 16 patients, and 30 infections required treatment when B cells were depleted.

"Rituximab [appears] effective and safe for induction and maintenance of remission in patients with relapsing GPA," Cartin-Ceba and colleagues conclude. "Preemptive retreatment decisions can be individualized based on serial B lymphocyte and PR3-ANCA monitoring."

Several authors disclosed being investigators on clinical trials supported by pharmaceutical companies, including Genentech, which manufactures .

Explore further: B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Brentuximab vedotin effective in large-cell lymphoma

May 24, 2012

(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete remission, ...

Recommended for you

Low vitamin D tied to dry eye syndromes

August 23, 2015

(HealthDay)—Patients with vitamin D deficiency should be evaluated for dry eye syndromes, according to a study published online Aug. 13 in the International Journal of Rheumatic Diseases.

Yoga improves arthritis symptoms and mood, study finds

September 15, 2015

A randomized trial of people with two common forms of arthritis has found that yoga can be safe and effective for people with arthritis. Johns Hopkins researchers report that 8 weeks of yoga classes improved the physical ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.